332 related articles for article (PubMed ID: 34680329)
1. Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T.
Crees ZD; Ghobadi A
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680329
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.
Meng J; Wu X; Sun Z; Xun R; Liu M; Hu R; Huang J
Front Oncol; 2021; 11():698607. PubMed ID: 34381720
[TBL] [Abstract][Full Text] [Related]
3. CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences.
Vitale C; Strati P
Front Oncol; 2020; 10():849. PubMed ID: 32670869
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
Nath K; Wudhikarn K; Alarcon Tomas A; Perales MA
Expert Opin Drug Saf; 2023 Jan; 22(1):5-15. PubMed ID: 36737060
[TBL] [Abstract][Full Text] [Related]
5. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
Reagan PM; Friedberg JW
Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
[TBL] [Abstract][Full Text] [Related]
6. Engineered T Cells: CAR T Cell Therapy and Beyond.
Johnson PC; Abramson JS
Curr Oncol Rep; 2022 Jan; 24(1):23-31. PubMed ID: 35059997
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
8. The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?
Knight E T; Oluwole O; Kitko C
Clin Hematol Int; 2024; 6(1):96-115. PubMed ID: 38817691
[TBL] [Abstract][Full Text] [Related]
9. CAR T-cell therapy for B-cell lymphoma.
Denlinger N; Bond D; Jaglowski S
Curr Probl Cancer; 2022 Feb; 46(1):100826. PubMed ID: 35012754
[TBL] [Abstract][Full Text] [Related]
10. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
Chow VA; Shadman M; Gopal AK
Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
[TBL] [Abstract][Full Text] [Related]
11. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
12. Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Perales MA; Anderson LD; Jain T; Kenderian SS; Oluwole OO; Shah GL; Svoboda J; Hamadani M
Transplant Cell Ther; 2022 Sep; 28(9):546-559. PubMed ID: 35768052
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
Abramson JS
Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Kallam A; Vose JM
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):751-757. PubMed ID: 31648957
[TBL] [Abstract][Full Text] [Related]
16. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies.
Al-Juhaishi T; Ahmed S
Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.
Makita S; Imaizumi K; Kurosawa S; Tobinai K
Drugs Context; 2019; 8():212567. PubMed ID: 30815024
[TBL] [Abstract][Full Text] [Related]
18. CAR T Cells.
Nair R; Westin J
Adv Exp Med Biol; 2021; 1342():297-317. PubMed ID: 34972970
[TBL] [Abstract][Full Text] [Related]
19. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma.
Deshpande A; Wang Y; Munoz J; Jain P
Drugs Today (Barc); 2022 Jun; 58(6):283-298. PubMed ID: 35670706
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]